Modestly weighted logrank tests

Abstract

We propose a new class of weighted logrank tests (WLRTs) that control the risk of concluding that a new drug is more efficacious than standard of care, when, in fact, it is uniformly inferior. Perhaps surprisingly, this risk is not controlled for WLRT in general. Tests from this new class can be constructed to have high power under a delayed‐onset treatment effect scenario, as well as being almost as efficient as the standard logrank test under proportional hazards.